Views & Analysis | Perspectives on pharma industry issues

Oncology

Unlocking the scalability of allogeneic CAR-T

Allogeneic CAR-T, built from healthy donor T-cells, offers a different path toward scale, accessibility, and consistency.

R&D

Why every healthcare breakthrough creates a new education ch...

Patients will only benefit from a health breakthrough if HCPs and the systems around them are able to put it into practice.

Sales & Marketing

Female HCP in her office on phone holding clipboard of patient information

Sponsored

Commercial Evidence: Turning field intelligence into actiona...

Agentic Call Reports help turn field observations into scalable, actionable insights generating Commercial Evidence.

Digital

Healthcare AI’s off switch needs a budget

An AI system can be cheap to buy and expensive to stop.

Patients

Union Jack on pill, one of many scattered on aqua surface

Rare diseases, real opportunity: Why the UK’s next challenge...

The UK has the science, the talent, and the investment. The next step is ensuring that innovation translates into timely patient impact.

Articles

Understanding “strategy”

Welcoming back a previous author now in a new role, pharmaphorum finds Pete West perplexed to find so many people talking at cross-purposes about strategy. Have you ever been half way through a conversation with someone and suddenly realised that the thing you thought you were discussing...

Articles

How about considering profitable segmentation?

As competition continues to increase within the pharmaceutical world, Dr. Andree Bates advises on the benefits of customer segmentation and targeted marketing. In today’s dynamic and competitive pharmaceutical environment, being able to effectively target your…

Articles

What Are IDEAs Made Of: Communications

As means and methods of communications expand, Mike Rea asks whether we are focusing too much on the how and losing sight of the what. It used to be that those involved in the process of communication understood which part of the process they were delivering against. Whether you use...

Sales & Marketing

Sponsored

Commercial Evidence: Turning field intelligence into actiona...

Agentic Call Reports help turn field observations into scalable, actionable insights generating Commercial Evidence.

Sales & Marketing

The independent pharmacy opportunity pharma marketers are ov...

Pharma marketers often underestimate the value of independent pharmacies.

Digital

Healthcare AI’s off switch needs a budget

An AI system can be cheap to buy and expensive to stop.

Digital

Sponsored

AI-enabled pharmacovigilance, with Updesh Dosanjh

Updesh Dosanjh, IQVIA commercialisation lead for safety technology, discusses how and why the role of AI in pharmacovigilance is changing.

Market Access

Chinese flag atop pills on black background

Is the next generation of Chinese biotech ready to go global...

Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?

Market Access

Two business hands outstretched, one weighing cash, the other drugs, for balance

What the revised 340B rebate pilot programme means for pharm...

While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.

Oncology

Unlocking the scalability of allogeneic CAR-T

Allogeneic CAR-T, built from healthy donor T-cells, offers a different path toward scale, accessibility, and consistency.

Oncology

Australia, CAR-T therapy, and solid tumours

Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.

Oncology